PCP
MRNA icon

Proficio Capital Partners’s Moderna MRNA Stock Holding History

Proficio Capital Partners’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-3,261
Closed -$218K – 373
2024
Q3 		$218K Sell
3,261
-667
-17% -$61.2K 0.02% 264
2024
Q2 		$466K Buy
3,928
+158
+4% +$20K 0.05% 173
2024
Q1 		$402K Buy
3,770
+376
+11% +$37.9K 0.04% 197
2023
Q4 		$338K Sell
3,394
-3
-0.1% -$252 0.04% 200
2023
Q3 		$351K Buy
+3,397
New +$379K 0.05% 190
2022
Q1 		– Sell
-979
Closed -$249K – 317
2021
Q4 		$249K Sell
979
-13
-1% -$3.8K 0.03% 253
2021
Q3 		$382K Sell
992
-105
-10% -$38.7K 0.05% 176
2021
Q2 		$258K Buy
+1,097
New +$196K 0.03% 237
2019
Q3 		– Sell
-67
Closed -$1K – 994
2019
Q2 		$1K Buy
+67
New +$1.44K ﹤0.01% 1762

Other funds holding MRNA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Proficio Capital Partners's MRNA Position: Q4 2024 in Review

Proficio Capital Partners sold out of Moderna (MRNA) in Q4 2024, closing a stake of 3,261 shares — an estimated $218K sold.

Proficio Capital Partners first reported a position in MRNA in Q2 2019 and held it in 9 quarters. The position peaked at $466K in Q2 2024. 745 funds tracked by Wall St. Rank hold MRNA as of Q4 2024.

  • Proficio Capital Partners reported no remaining Moderna position as of Q4 2024 after selling out during the quarter.
  • Proficio Capital Partners sold 3,261 Moderna shares in Q4 2024, an estimated $218K.
  • Proficio Capital Partners first reported a position in Moderna in Q2 2019 and held it in 9 quarters.
  • Proficio Capital Partners's Moderna position peaked at $466K in Q2 2024.
  • 745 funds tracked by Wall St. Rank held Moderna as of Q4 2024.

Based on Proficio Capital Partners's 13F filing for Q4 2024, filed 5 Feb 2025.